| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b4a80ac02f1ecd0e698ec665e9b36b6 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2022
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2017-11-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b02bb03a54571c3eaf61bd7a71abdcfd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d478d753683c04bf7d1fa0703dc53bb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_112558250fd5311379568744e339f2ac
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad4b3696bc767a642e0fd1a76961a39d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_39f00a0a58ec36a8410c7bf38990b96a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1b8e7ea1e13bf6c05f5fd21c889d640
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a0e3ad33dcf4bcfccec7010fb9690d3d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4c79a3fb0a56bce7f68d0b660c6c0ce0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3441f502086766605aeec8d9d2f227de |
| publicationDate |
2018-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20180058644-A |
| titleOfInvention |
Sustained release pharmaceutical formulation of varenicline and preparation method thereof |
| abstract |
The present invention provides an oral sustained release preparation characterized by being a sustained release matrix system comprising barrenicin or a pharmaceutically acceptable salt thereof and a matrix polymer. The present invention can provide a sustained-release preparation having increased adherence compliance and reduced side effects by once-a-day administration. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102235848-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20200034293-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023085503-A1 |
| priorityDate |
2016-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |